Patentability criteria and exemption from patentability based on what constitutes novelty. | Namibia, Rwanda and Zambia have specifically legislated against new or second use of already patented pharmaceutical products to stop “ever-greening” of patents | |
Research exception | Algeria, Botswana, Burundi, Cabo Verde, Democratic Republic of Congo, Eswatini, Ethiopia, Ghana, Kenya, Lesotho, Liberia, Madagascar, Mauritius, Mozambique, Namibia, Rwanda, Sao Tome & Principe, Seychelles, Sierra Leone, Tanzania, Uganda, | OAPI countries –Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Comoros, Congo, Cote d’Ivoire, Equatorial Guinea, Gabon, Guinea, Guinea Bissau, Mali, Mauritania, Niger, Senegal and Togo do not provide legislative exceptions for research purposes. |
Regulatory review exception (Bolar exception) | Botswana, Cabo Verde, Kenya, Liberia, Namibia, Rwanda, Sao Tome & Principe, Seychelles, South Africa, Uganda, Zambia, Zimbabwe | OAPI countries –Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Comoros, Congo, Cote d’Ivoire, Equatorial Guinea, Gabon, Guinea, Guinea Bissau, Mali, Mauritania, Niger, Senegal and Togo do not provide legislative exceptions for regulatory review purposes. |
Compulsory licensing | Algeria, Angola, Botswana, Burundi, Cabo Verde, Democratic Republic of Congo, Eswatini, Ethiopia, The Gambia, Ghana, Kenya, Lesotho, Liberia, Malawi, Mozambique, Namibia, Nigeria, Rwanda, Sierra Leone, Sao Tome & Principe, Seychelles, South Africa, South Sudan, Tanzania, Uganda, Zambia, Zimbabwe, and OAPI countries namely Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Comoros, Congo, Cote d’Ivoire, Equatorial Guinea, Gabon, Guinea, Guinea Bissau, Mali, Mauritania, Mauritius, Niger, Senegal and Togo. | |
Exhaustion of rights and parallel importation | International exhaustion – Botswana, Burundi, Ghana, Kenya, Liberia, Mauritius, Namibia, Seychelles, Sierra Leone, South Africa, Zambia, Zimbabwe Regional Exhaustion – Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Congo Republic, Cote d’Ivoire, Equatorial Guinea, Gabon, Guinea, Guinea-Bissau, Mali, Mauritania, Niger, Senegal, Togo – essentially all OAPI countries. National exhaustion – Eswatini, The Gambia, Lesotho, Rwanda, Madagascar, Mozambique, and Tanzania, Nigeria, Sao Tome & Principe, South Sudan, Uganda Algeria – legislationa does not specify applicable level of exhaustion whether national or international | |
Patent term extension | Angolab, Zimbabwec | |
Limits on test data protection | Uganda | |
Transition periods for LDCs and exemption of pharmaceutical products from patentable subject matter | Angola, Burundi, Madagascar, Liberia, Rwanda, Uganda have excluded pharmaceutical products from patentability criteria | OAPI countries –Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Comoros, Congo, Cote d’Ivoire, Equatorial Guinea, Gabon, Guinea, Guinea Bissau, Mali, Mauritania, Niger, Senegal and Togo, do not exempt pharmaceutical products from patentable subject matter. |
Enactment of a patent opposition system | Countries with a pre-grant opposition system: - Botswana, Burundi, Cabo Verde, Lesotho, Liberia, Malawi, Mozambique, Namibia, Seychelles, Uganda, Zambia, Zimbabwe Countries with a post-grant opposition system: - Botswana, Comoros, DRC, Eswatini, Gambia, Ghana, Kenya, Lesotho, Liberia, Malawi, Mauritius, Mozambique, Namibia, Rwanda, Sao Tome & Principe, Seychelles, South Africa, South Sudan, Tanzania, Uganda, Zambia, Zimbabwe | OAPI countries –Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Comoros, Congo, Cote d’Ivoire, Equatorial Guinea, Gabon, Guinea, Guinea Bissau, Mali, Mauritania, Niger, Senegal and Togo do not have patent opposition legislation. |